Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15233017rdf:typepubmed:Citationlld:pubmed
pubmed-article:15233017lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0151779lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0334424lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C2739810lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0003324lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0332261lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:15233017lifeskim:mentionsumls-concept:C0680536lld:lifeskim
pubmed-article:15233017pubmed:issue2lld:pubmed
pubmed-article:15233017pubmed:dateCreated2004-7-5lld:pubmed
pubmed-article:15233017pubmed:abstractTextIn certain primary and metastatic malignant melanomas diagnostic problems may arise due to their cytologic features and/or absence of synthesis of melanin. As the "classic" combination of S-100 protein and HMB-45 may occasionally fail to stain cells of malignant melanoma, we have tested a series of commercially accessible antibodies which were so far not compared by other authors in the three most frequent subtypes of this tumor. In surgical specimens from 104 cutaneous malignant melanomas (40 nodular melanomas, 46 superficially spreading malignant melanomas and 18 lentigo maligna melanomas) the staining intensity and the proportion of neoplastic cells stained with antibodies to S-100 protein, HMB-45, NKI/C3, NKI/beteb, MART 1 (Melan A), KBA 62 and Mitf was semiquantitatively analysed. The use of this group of antibodies against melanoma-associated antigens revealed it to be a favourable supplement for the bioptical or cytological diagnosis of malignant melanoma in case the traditional/conventional combination of S-100 protein and HMB-45 antibody fails. According to the authors' experience the antibody against KBA 62 has shown to be the most effective antibody followed by the antibodies against MART-1 (Melan A) and NKI/C3.lld:pubmed
pubmed-article:15233017pubmed:languageenglld:pubmed
pubmed-article:15233017pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233017pubmed:citationSubsetIMlld:pubmed
pubmed-article:15233017pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233017pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233017pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233017pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233017pubmed:statusMEDLINElld:pubmed
pubmed-article:15233017pubmed:monthAprlld:pubmed
pubmed-article:15233017pubmed:issn1210-7875lld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:JurkovicIIlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:BöörAAlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:KrajcárRRlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:DudríkováKKlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:BenickýMMlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:KocanPPlld:pubmed
pubmed-article:15233017pubmed:authorpubmed-author:KromydakiAAlld:pubmed
pubmed-article:15233017pubmed:issnTypePrintlld:pubmed
pubmed-article:15233017pubmed:volume40lld:pubmed
pubmed-article:15233017pubmed:ownerNLMlld:pubmed
pubmed-article:15233017pubmed:authorsCompleteYlld:pubmed
pubmed-article:15233017pubmed:pagination50-6lld:pubmed
pubmed-article:15233017pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:meshHeadingpubmed-meshheading:15233017...lld:pubmed
pubmed-article:15233017pubmed:year2004lld:pubmed
pubmed-article:15233017pubmed:articleTitleImmunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one non-commercial antibody in nodular melanoma, superficially spreading melanoma and lentigo maligna melanoma.lld:pubmed
pubmed-article:15233017pubmed:affiliationInstitute of Pathology, Faculty of Medicine, P. J. Safárik University, Kosice, Slovak Republic. palokocan@centrum.sklld:pubmed
pubmed-article:15233017pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15233017pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15233017pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15233017lld:pubmed